Next Article in Journal
Bacterial Expression and Kinetic Analysis of Carboxylesterase 001D from Helicoverpa armigera
Next Article in Special Issue
Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD
Previous Article in Journal
Characterization of Virulence Properties of Aeromonas veronii Isolated from Diseased Gibel Carp (Carassius gibelio)
Previous Article in Special Issue
Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(4), 490; doi:10.3390/ijms17040490

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant

Department of Gastroenterology, Azienda Ospedaliero-Universitaria and University of Modena and Reggio Emilia, Via del Pozzo 1, 41124 Modena, Italy
Author to whom correspondence should be addressed.
Academic Editors: Amedeo Lonardo and Giovanni Targher
Received: 16 March 2016 / Revised: 25 March 2016 / Accepted: 28 March 2016 / Published: 2 April 2016
(This article belongs to the Special Issue Non-Alcoholic Fatty Liver Disease Research 2016)
View Full-Text   |   Download PDF [208 KB, uploaded 2 April 2016]   |  


Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage liver disease, with or without hepatocellular carcinoma. Increase of body weight, onset of insulin resistance and drug-induced alterations of metabolism are reported in liver transplant recipients. In this context, post-transplant diabetes mellitus, hyperlipidemia, and arterial hypertension can be often diagnosed. Multifactorial illnesses occurring in the post-transplant period represent significant causes of morbidity and mortality. This is especially true for metabolic syndrome. Non-alcoholic steatosis and steatohepatitis are hepatic manifestations of metabolic syndrome and after liver transplant both recurrent and de novo steatosis can be found. Usually, post-transplant steatosis shows an indolent outcome with few cases of fibrosis progression. However, in the post-transplant setting, both metabolic syndrome and steatosis might play a key role in the stratification of morbidity and mortality risk, being commonly associated with cardiovascular disease. The single components of metabolic syndrome can be treated with targeted drugs while lifestyle intervention is the only reasonable therapeutic approach for transplant patients with non-alcoholic steatosis or steatohepatitis. View Full-Text
Keywords: liver transplant; multifactorial disease; metabolic syndrome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis liver transplant; multifactorial disease; metabolic syndrome; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gitto, S.; Villa, E. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant. Int. J. Mol. Sci. 2016, 17, 490.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top